check_circleStudy Completed
Atrial Fibrillation (Prevention of Stroke)
Bayer Identifier:
18073
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Real-Life Evidence on Stroke Prevention in SPAF
Trial purpose
To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF) in a real-life setting
Key Participants Requirements
Sex
BothAge
18 - N/ATrial summary
Enrollment Goal
8607Trial Dates
May 2015 - August 2015Phase
N/ACould I Receive a placebo
NoProducts
Xarelto (Rivaroxaban, BAY59-7939)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many Locations, Germany |
Primary Outcome
- Time to first occurrence of any of the following: Ischemic stroke (IS), Transient ischemic attack (TIA), Intracerebral hemorrhage (IH), Other non-traumatic intracranial hemorrhage including subdural hemorrhage, Myocardial infarction (MI)Composite cardiovascular endpointdate_rangeTime Frame:Within 1 year after treatment startenhanced_encryptionNoSafety Issue:
Secondary Outcome
- Time to first occurrence of ISSingle cardiovascular eventdate_rangeTime Frame:Within 1 year after treatment startenhanced_encryptionNoSafety Issue:
- Time to first occurrence of TIASingle cardiovascular eventdate_rangeTime Frame:Within 1 year after treatment startenhanced_encryptionNoSafety Issue:
- Time to first occurrence of IHSingle cardiovascular eventdate_rangeTime Frame:Within 1 year after treatment startenhanced_encryptionNoSafety Issue:
- Time to first occurrence of Other non-traumatic intracranial hemorrhage including subdural hemorrhageSingle cardiovascular eventdate_rangeTime Frame:Within 1 year after treatment startenhanced_encryptionNoSafety Issue:
- Time to first occurrence of MISingle cardiovascular eventdate_rangeTime Frame:Within 1 year after treatment startenhanced_encryptionNoSafety Issue:
- Incidence density in study population of ISdate_rangeTime Frame:Within 1 year after treatment startenhanced_encryptionNoSafety Issue:
- Incidence density in study population of TIAdate_rangeTime Frame:Within 1 year after treatment startenhanced_encryptionNoSafety Issue:
- Incidence density in study population of IHdate_rangeTime Frame:Within 1 year after treatment startenhanced_encryptionNoSafety Issue:
- Incidence density in study population of Other non-traumatic intracranial hemorrhage including subdural hemorrhagedate_rangeTime Frame:Within 1 year after treatment startenhanced_encryptionNoSafety Issue:
- Incidence density in study population of MIdate_rangeTime Frame:Within 1 year after treatment startenhanced_encryptionNoSafety Issue:
- Incidence density in study population of any of the following: IS, TIA, IH, Other non-traumatic intracranial hemorrhage including subdural hemorrhage, MIdate_rangeTime Frame:Within 1 year after treatment startenhanced_encryptionNoSafety Issue:
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A